Tanezumab, identified by the chemical designation 880266-57-9, represents a targeted antibody reagent demonstrating significant potential in alleviating debilitating osteoarthritis pain. This modified antibody selectively targets pain growth element , inhibiting its effect and thereby diminishing inflammation within affected joints . The ongoing data surrounding 880266-57-9 highlights its power to offer substantial suffering reduction while potentially mitigating the requirement for traditional analgesics. Further studies are diligently underway to thoroughly assess its sustained safety and effectiveness .

Comprehending Tanezumab's Part in Discomfort Alleviation: An Antibody Perspective

Tanezumab, a groundbreaking treatment approach, offers a unique pathway in persistent pain management. As a humanized antibody, it precisely targets and prevents nerve expansion factor (NGF), a key molecule engaged in nerve discomfort signaling. Unlike traditional opioid medications, tanezumab’s immune mechanism allows for a more specific action, potentially lessening the risk of some frequent side reactions connected with generalized pain relief. However, its body's defense nature necessitates a detailed assessment of potential allergic effects and sustained consequences when administered within a complete pain therapy program.

Tanezumab Compound (880266-57-9): Quality , Purity & Functions

The Tanezumab Reagent with the identifier 880266-57-9 is a essential component in various research applications, particularly concerning joint pain treatment development. Achieving a high degree of quality is paramount; therefore, rigorous assessment protocols are employed to guarantee its appropriateness for intended use. Our creation procedure focuses on ensuring refinement, employing sophisticated separation techniques to remove impurities . Typical parameters include a >95% purity assessment as determined by Chromatography and comprehensive examination for protein integrity. The main uses revolve around its role as a research tool for investigating pathways of arthritis progression and developing novel therapeutic interventions .

• Scientific Investigations
• Medical Development
• Process Studies

A Investigation Regarding Tanezumab: Exploring the 880266-57-9 Antibody

Tanezumab, identified with the molecular identifier 880266-57-9, represents a groundbreaking biological protein targeting nerve development agent receptor (NGF). This process of action revolves around selectively connecting to NGF, thereby inhibiting its function and subsequent signal propagation. Investigators have shown that read more this biological molecule presents promise for managing severe pain, particularly in diseases like osteoarthritis and chronic back pain. Additional investigations are continuing to completely define its impact and safety profile.

New Developments in This Research: Focusing on the 880266-57-9 Compound

Ongoing research surrounding tanezumab, a promising therapeutic agent, are increasingly directed on understanding the role of the specific reagent, compound 880266-57-9. The detection and detailed assessment of this biological entity appears vital for optimizing tanezumab's performance and minimizing possible negative outcomes. Initial data suggest that 880266-57-9 functions a significant part in the therapy's process of action. Additional investigations remain essential to fully clarify its effect.

Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential

The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}